PUBLISHER: 360iResearch | PRODUCT CODE: 1861928

PUBLISHER: 360iResearch | PRODUCT CODE: 1861928

PET-CT Scanners Market by Application, Device Type, End User, Service Type, Gantry Type - Global Forecast 2025-2032

PUBLISHED: September 30, 2025

PAGES: 184 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The PET-CT Scanners Market is projected to grow by USD 4.27 billion at a CAGR of 5.31% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 2.82 billion
Estimated Year [2025]	USD 2.97 billion
Forecast Year [2032]	USD 4.27 billion
CAGR (%)	5.31%

A strategic orientation to PET-CT imaging that frames its clinical relevance, technological evolution, and implications for procurement and service delivery within healthcare systems

Positron emission tomography-computed tomography (PET-CT) has evolved into a cornerstone imaging modality, uniquely positioned at the intersection of functional and anatomical diagnostics. Its capacity to visualize metabolic activity alongside morphological detail underpins crucial clinical pathways across oncology, cardiology, and neurology, while supporting research and theranostic applications. Beyond clinical value, PET-CT systems shape workflows, capital planning, and service models for hospitals, diagnostic centers, and research institutions.

Technological progress in detector materials, image reconstruction algorithms, and integrated software platforms has enhanced image fidelity, scan speed, and quantitative accuracy. These advances, together with growing interest in novel radiotracers and hybrid diagnostic-therapeutic protocols, have redefined expectations for diagnostic yield and patient throughput. As a result, stakeholders must navigate a more complex procurement landscape where device capabilities, tracer ecosystems, and service commitments converge to influence clinical and economic outcomes.

In this context, strategic decision-making requires a holistic view that encompasses device architecture, gantry performance, service and upgrade pathways, and end-user operational needs. The subsequent sections synthesize transformative shifts affecting technology adoption, trade-policy headwinds, segmentation nuances, regional dynamics, competitive imperatives, and actionable steps for leaders. The aim is to provide a structured narrative that supports informed choices across clinical, financial, and regulatory domains.

How detector innovation, AI-enabled software, evolving tracer ecosystems, and new deployment models are jointly reshaping clinical workflows, procurement, and service strategies

The landscape for PET-CT systems is undergoing several convergent shifts that are transforming clinical workflows, supply chains, and commercialization strategies. Rapid improvements in detector sensitivity and reconstruction techniques are enabling shorter scan times and finer lesion detectability, yielding tangible workflow efficiencies and diagnostic confidence. Concurrently, software-driven advancements-particularly in artificial intelligence and quantitative imaging-are increasing the value of integrated platforms that offer decision support, automated quality control, and streamlined reporting.

On the operational front, healthcare providers are evaluating new deployment models that balance fixed installations with mobile or decentralized services to reach underserved populations and optimize scanner utilization. This transition is reinforced by a growing emphasis on service contracts, remote diagnostics, and preventive maintenance programs that preserve uptime and extend asset life. At the same time, the tracer ecosystem is diversifying: while established radiotracers remain central, research into non-FDG agents and theranostic pairs is accelerating, prompting closer collaboration between device manufacturers, radiopharmaceutical suppliers, and clinical teams.

Finally, regulatory expectations and reimbursement frameworks are evolving to address quality assurance, data governance, and value-based care. These changes are encouraging vendors and providers to prioritize interoperable systems, robust documentation, and outcomes-oriented evidence generation. Taken together, these transformative shifts are elevating the role of integrated technology-service partnerships and strategic planning in shaping how PET-CT capabilities are acquired, deployed, and sustained.

Assessing how recent tariff adjustments have altered sourcing economics, supply chain resilience, and procurement strategies for imaging hardware and critical components

The cumulative impact of tariff changes imposed by a major economy has created a set of operational and strategic effects that stakeholders must weigh carefully. Increased import duties on imaging hardware and components typically result in higher landed costs for end users, prompting procurement teams to reassess total cost of ownership considerations and to explore alternative sourcing strategies. As tariffs render some supply routes less economical, manufacturers and suppliers may accelerate localization of manufacturing, diversify sourcing footprints, or reconfigure component sourcing to mitigate exposure to trade barriers.

Beyond immediate cost implications, tariff-driven shifts can introduce friction into existing supply chains, generating longer lead times for critical spare parts and replacement modules. This risk underscores the importance of service resilience and inventory planning for providers that rely on rapid access to components to maintain clinical continuity. Moreover, regulatory compliance and customs procedures can add administrative burden to cross-border transactions, influencing contract terms, warranty structures, and the negotiation of service-level agreements.

In response, stakeholders tend to recalibrate procurement strategies, increase emphasis on modular designs that facilitate local assembly or repair, and strengthen partnerships with regional distributors and service providers. Concurrently, there is a tendency to prioritize devices with lower import intensity or to leverage financing mechanisms that smooth capital expenditure impacts. Taken together, these adaptations demonstrate how trade policy shocks propagate across the ecosystem, affecting capital decisions, service reliability, and the pace at which new technologies are adopted.

Segmentation-driven insights that connect clinical applications, device typologies, end-user requirements, service modalities, and gantry architectures to strategic decision-making

A nuanced understanding of product and service segmentation is essential to align technology offerings with clinical use cases and institutional capabilities. In terms of clinical application, cardiology, neurology, and oncology represent distinct demand drivers; oncology remains particularly dynamic, with differentiation between FDG-based imaging that supports broad metabolic assessment and non-FDG tracers that target specific biological pathways or receptor profiles. These application-level distinctions influence scanner selection criteria, tracer logistics, and the design of imaging protocols.

Device type considerations further refine deployment decisions. Fixed systems typically serve high-volume centers where throughput and comprehensive functionality are priorities, while mobile units provide flexibility for outreach programs and shared-service arrangements among smaller institutions. End-user diversity matters as well: diagnostic centers prioritize throughput and ease of scheduling, hospitals balance inpatient and outpatient workflows and may require integrated electronic health record connectivity, and research institutes value modularity and advanced quantitative capabilities. Within hospital settings, private facilities often emphasize customer experience and value-added service agreements, whereas public hospitals focus on cost-effectiveness and broad access.

Service type choices-installation, maintenance, and upgrades-determine long-term performance and lifecycle economics. Proactive maintenance regimes and structured upgrade paths can extend useful life and preserve image quality, while installation quality affects initial calibration and regulatory compliance. Gantry architecture, whether multi-slice or single-slice, has implications for spatial resolution, scan time, and compatibility with advanced reconstruction techniques. Integrating these segmentation lenses yields a comprehensive foundation for matching product roadmaps and service models to market needs.

Regional nuances across the Americas, Europe-Middle East-Africa, and Asia-Pacific that shape procurement preferences, service models, and tracer logistics across diverse healthcare systems

Regional dynamics create varied demand characteristics and operational considerations that influence how stakeholders prioritize investment and deployment. In the Americas, healthcare systems display a wide spectrum of payer models and capital financing approaches, and large tertiary centers often act as early adopters of advanced imaging modalities. As a result, emphasis is placed on integrated workflows, robust service networks, and compatibility with a range of radiotracers to support complex oncologic, neurologic, and cardiac imaging programs.

The Europe, Middle East & Africa region encompasses diverse regulatory environments and procurement modalities, driving a need for adaptable commercial strategies. In several markets, publicly funded health systems prioritize cost-effective solutions and long-term maintenance agreements, while private centers compete on service differentiation and rapid access. Cross-border collaboration and regional distribution partnerships are common approaches to address logistical challenges and to ensure continuity of tracer supply in markets with limited cyclotron infrastructure.

Asia-Pacific presents a broad mix of rapidly expanding capacity and technology adoption alongside mature centers of excellence. High population density in large metropolitan areas creates demand for scalable solutions, including mobile deployments to extend access to peripheral regions. Additionally, local manufacturing initiatives and strategic alliances between global vendors and regional partners are influencing product localization, regulatory submission timelines, and aftermarket service models. Understanding these regional nuances is essential for aligning product offerings and service footprints with on-the-ground operational realities.

How competitive advantage is shifting toward integrated platforms that combine hardware performance, software intelligence, service excellence, and strategic tracer partnerships

Competitive dynamics are increasingly defined by the interplay between hardware innovation, software ecosystems, and service excellence. Leading suppliers pursue strategies that combine platform performance with scalable software solutions that enable quantitative imaging, workflow automation, and remote diagnostics. Partnerships with radiopharmaceutical suppliers and research institutions are becoming central to differentiated value propositions, enabling tailored tracer-support programs and clinical evidence generation that reinforce diagnostic positioning.

Service and aftermarket offerings represent a growing revenue and differentiation vector. Extended warranties, performance-based service contracts, and remote-monitoring capabilities are being positioned to reduce downtime and provide predictable lifecycle economics for providers. At the same time, modular hardware architectures and upgrade pathways help vendors preserve installed-base relationships while offering incremental feature improvements without complete system replacement.

Collaborative commercialization models-ranging from joint ventures to localized manufacturing and distribution agreements-help vendors address tariff exposures and regulatory complexities in target markets. In parallel, some companies are investing in training and accreditation programs for clinical teams to support advanced protocols and novel tracers, thereby accelerating clinical adoption. Together, these strategic moves indicate that competitive advantage increasingly hinges on integrated solutions that combine technical excellence with service depth, regulatory insight, and clinical partnership.

Practical, prioritized recommendations for manufacturers, providers, and distributors to strengthen supply resilience, expand service value, and accelerate clinical adoption of PET-CT technologies

To capture both clinical impact and commercial value, industry leaders should adopt a set of pragmatic, prioritized actions that balance near-term resilience with long-term positioning. First, diversify supply chains and evaluate opportunities for regional assembly or local partnerships to reduce exposure to trade-policy disruptions and to shorten lead times for critical spares. This pragmatic approach will strengthen service continuity and provide procurement flexibility across different payer environments.

Second, invest in software and analytics capabilities that enhance image quantitation, workflow automation, and remote service diagnostics. These capabilities not only improve diagnostic consistency but also create recurring value through service subscriptions and platform monetization. Third, expand service footprints through preventive maintenance programs, extended warranties, and outcome-oriented service contracts that align vendor incentives with clinical uptime and image quality.

Fourth, pursue tracer and research collaborations to broaden clinical applications beyond conventional agents, supporting theranostic programs and specialty imaging needs. Fifth, tailor commercial models to regional realities by offering modular financing, mobile deployment options, and training programs that build local clinical capacity. Finally, engage proactively with regulators and payers to align evidence generation plans with reimbursement expectations and quality frameworks, ensuring smoother adoption pathways and sustained clinical impact.

A transparent, mixed-methods research approach that blends primary interviews, technical reviews, regulatory analysis, and cross-validation to ensure robust, actionable insights

The research synthesis underpinning this report is grounded in a mixed-methods approach that emphasizes triangulation of primary insights, technical literature, and regulatory documentation. Primary research included structured interviews with clinical leaders, imaging physicists, service managers, and procurement specialists to elicit operational challenges, technology priorities, and decision criteria across diverse care settings. These qualitative inputs were complemented by device-level technical reviews, peer-reviewed publications, and public regulatory filings to validate performance attributes and compliance pathways.

Secondary evidence streams involved analysis of clinical trial registries, tracer development pipelines, and conference proceedings to capture emerging applications and technology directions. Where applicable, anonymized case studies and operational audits informed assessments of installation practices, maintenance regimes, and service model efficacy. Throughout the process, findings were cross-validated with subject-matter experts to ensure accuracy and to surface divergent perspectives.

Limitations were acknowledged and addressed through sensitivity checks and methodological safeguards. Data quality controls included source verification, reviewer adjudication, and a clear audit trail for inferential claims. The methodology emphasizes transparency and reproducibility, providing clients with confidence in the reliability of the insights and the contextual relevance for strategic decision-making.

Concluding synthesis that links technological advances, service models, and policy dynamics to strategic imperatives for optimizing PET-CT deployment, clinical value, and resilience

The synthesis presented throughout this executive summary underscores that PET-CT remains a critical diagnostic and research tool whose strategic value is amplified by recent technological and organizational shifts. Innovations in detector technology, reconstruction algorithms, and software-driven workflow enhancements are increasing diagnostic yield and operational efficiency, while evolving tracer landscapes and hybrid clinical paradigms expand the modality's clinical footprint. At the same time, trade-policy perturbations and regional nuances in procurement, regulation, and infrastructure create differentiated operational challenges and strategic opportunities.

For stakeholders, the imperative is to think holistically: align product design with service offerings, build supply chains that reduce exposure to external shocks, and invest in software and clinical partnerships that generate sustained value. By doing so, manufacturers, providers, and distributors can ensure that PET-CT capabilities deliver both improved patient outcomes and predictable operational performance. The insights and recommendations in this report are intended to inform capital allocation, product roadmaps, and collaborative strategies that will shape the next phase of PET-CT adoption and clinical integration.

Product Code: MRR-521BAA36EA75

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Integration of artificial intelligence and deep learning algorithms into PET-CT imaging workflows to enhance diagnostic accuracy in oncology patients
5.2. Development and commercialization of total-body PET-CT systems offering whole-body dynamic imaging with high sensitivity and reduced scan times
5.3. Adoption of novel radiotracers in PET-CT for immunoPET applications to monitor cancer immunotherapy response in real time
5.4. Emergence of portable and compact PET-CT scanners enabling point-of-care molecular imaging in rural and underserved healthcare facilities
5.5. Retrofitting existing PET-CT systems with silicon photomultiplier detectors to improve spatial resolution and quantitative accuracy
5.6. Regulatory approvals and reimbursement policy changes accelerating PET-CT adoption in Asia Pacific and Latin American healthcare markets
5.7. Collaborations between imaging centers and radiopharmaceutical companies to develop personalized PET-CT protocols for theranostic applications
5.8. Expansion of PET-CT clinical applications beyond oncology into neurology and cardiovascular disease diagnostics through innovative tracers
5.9. Integration of PET-CT data with advanced radiomics and precision medicine platforms for predictive analytics in cancer treatment planning

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. PET-CT Scanners Market, by Application

8.1. Cardiology
8.2. Neurology
8.3. Oncology
- 8.3.1. FDG Tracer
- 8.3.2. Non-FDG Tracer

9. PET-CT Scanners Market, by Device Type

9.1. Fixed
9.2. Mobile

10. PET-CT Scanners Market, by End User

10.1. Diagnostic Centers
10.2. Hospitals
- 10.2.1. Private Hospitals
- 10.2.2. Public Hospitals
10.3. Research Institutes

11. PET-CT Scanners Market, by Service Type

11.1. Installation
11.2. Maintenance
11.3. Upgrades

12. PET-CT Scanners Market, by Gantry Type

12.1. Multi-Slice
12.2. Single-Slice

13. PET-CT Scanners Market, by Region

13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
13.3. Asia-Pacific

14. PET-CT Scanners Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. PET-CT Scanners Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. Competitive Landscape

16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
- 16.3.1. General Electric Company
- 16.3.2. Siemens Healthineers AG
- 16.3.3. Koninklijke Philips N.V.
- 16.3.4. Canon Medical Systems Corporation
- 16.3.5. United Imaging Healthcare Co., Ltd.
- 16.3.6. Neusoft Corporation
- 16.3.7. Hitachi, Ltd.
- 16.3.8. Shimadzu Corporation
- 16.3.9. Analogic Corporation
- 16.3.10. Fujifilm Holdings Corporation